Shanghai Yizhong Biotechnology Co., Ltd., established on 2000-10-13, Business scope includes research on biomedical products and technologies,to develop,"Four skills"Serve.

Netherlands-based Glycostem Therapeutics BV, a clinical stage biotech company focused on developing off-the shelf allogeneic cellular immunotherapy using Natural Killer (NK) cells to treat several types of cancer. NK-cells are the body’s first line of defence because of the innate ability of NK-cells to rapidly and accurately identify and destroy cells under stress, such as cancer or virally-infected cells. Glycostem’s lead product, oNKord® , is produced in a closed system in Glycostem’s state-of-theart production facility in The Netherlands, from which the product can be distributed globally. The platform technology includes ex vivo expansion of a high number of pure and highly activated NK-cells for clinical applications. oNKord® successfully concluded phase I clinical trial (elderly and fragile AML patients), providing solid safety data and strong indication of clinical activity, including response on MRD. Glycostem expects to obtain GMP certification by the end of 2018 and is planning to enter pivotal clinical trial in Q1 2019. Thanks to the six patent families, longstanding technical expertise and resources, as well as ‘Orphan Drug Designation’, Glycostem has secured a leadership position in the global NK-cell market.

Hangzhou Hercules Medical Equipment Co., Ltd., established on 1998-09-02, Business scope includes licensed projects:Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).General project:Production of Class I Medical Devices;Sales of Class I Medical Devices;Class I Medical Device Leasing;Sales of Class II Medical Devices;Class II Medical Device Leasing;Optical Instrument Sales;Optical Instrument Manufacturing;Import and export;Instrument Repair;electronic,Mechanical equipment maintenance(No special equipment);Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

China Resources Double-Crane Pharmaceutical Co., Ltd. engages in the processing, manufacture, and sale of pharmaceutical, chemical, and biomedical raw materials. It operates through the following business segments: Infusion and Non-infusion. Its products include compound reserpine flattamine tablets, amlodipine besylate tablets, gliquidone tablets, citicoline sodium tablets, magnesium valproate sustained-release tablets, and soft bags. The company was founded on May 16, 1997 and is headquartered in Beijing, China.

Beijing Huayuan Bochuang Technology Co., Ltd., established on 2008-06-26, Business scope includes research,developing biotech drugs;technical consulting,Technical Services,technology transfer.(Enterprises independently choose operating projects according to law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. It operates through the following segments: Cell Medicine, Medical Support, and Pharmaceuticals. The Cell Medicine segment provides cancer treatment technology and know-hows centered on dendritic cell vaccine therapy. The Medical Support segment manages contact research organization (CRO) business and offers genetic testing services. The Pharmaceuticals segment deals with the development of dendritic cell vaccine as a cancer treatment. The company was founded by Yuichiro Yazaki on June 24, 2004 and is headquartered in Tokyo, Japan.

Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom.

Pfizer Inc. (NYSE: PFE, /ˈfaɪzər/) is an American multinational pharmaceutical corporation headquartered in New York City was founded in 1849, based in New York City and was listed on New York Stock Exchange. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

Shanghai Zhongyi Precision Medical Technology Co., Ltd., established on 2017-04-13, Business scope includes medical device technology,Technology development in the field of biotechnology,technology transfer,technical consulting,Technical Services,Instrumentation,chemical reagent(Removal of hazardous chemicals,Monitor Chemicals,civilian explosives,precursor chemicals),laboratory equipment,Sales of Medical Devices,account Serive,Exhibition display service,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Cytomatrix Pty Ltd., a subsidiary of SK3 Group, Inc., is a company headquartered in Waurn Ponds, Australia, focused on commercial physical and biological research. The firm was acquired by Healthcare of Today, Inc. on July 21, 2010.

The Research Authority serves as the administrative and financial framework for research activities, scientific experiments and technical analyses carried out by Technion faculty, and TRDF staff. The missions of the Research & Development Division are: - Location, collection, processing and distribution of information concerning local and international research funding - Assistance in locating appropriate funding sources for Technion researchers - R&D information management services and in-campus marketing - Guidance and administrative services for Technion researchers in submitting research proposals to granting agencies and business entities - Management of contractual engagements with granting agencies and business entities - Contractual and budgetary administration of research grants and other accounts

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Hunan Huilin Life Technology Co., Ltd., established on 2002-10-24, Business scope includes life science and technology,Stem Cell Technology Research,to develop,consultation service;biomedicine,medical instruments,Research and development of medical equipment and technical consulting services,Research on Experimental Equipment,to develop,Production,Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Dexerials Corp. engages in the manufacture and sale of optical, electronic and adhesive materials. It operates through the following segments: Optics Materials and Electronic Component Products segments. The Optic Materials segment provides optical elasticity resins(SVR), optical films, UV curable resin for optical disks, inorganic wave plates and inorganic polarizers. The Electronic Component Products segment provides industrial functional bonding material, anisotropic conductive film, surface mounted type fuse, and inorganic polarizing plate. The company was founded on March 5, 1962 and is headquartered in Tokyo, Japan.